Differential immunologic and microRNA effects of 2 dosing regimens of recombinant human granulocyte/macrophage colony stimulating factor

Journal of Immunotherapy

Volumn 35, Issue 7, 2012, Pages 587-594

  Triozzi, Pierre L ^a   Achberger, Susan ^a   Aldrich, Wayne ^a   Elson, Paul ^a   Garcia, Jorge ^a   Dreicer, Robert ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

dendritic cells; myeloid derived suppressor cells; prostate cancer; regulatory T cells

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 155; MICRORNA 223; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCHEMICAL RELAPSE; BONE MARROW CELL; CANCER GROWTH; CANCER RELAPSE; CELL ACTIVATION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DOSE REGIMEN; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MALE; MONOCYTE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; RNA ISOLATION; SUPPRESSOR CELL; TREATMENT DURATION;

ADENOCARCINOMA; AGED; BIOMARKERS, PHARMACOLOGICAL; CLINICAL PROTOCOLS; CYTOKINES; DENDRITIC CELLS; DRUG DOSAGE CALCULATIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSION; MALE; MICRORNAS; MIDDLE AGED; MYELOID CELLS; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84865528854     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31826b20b6     Document Type: Article

References (50)

1. Eksioglu EA, Mahmood SS, Chang M, et al. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007;35:1163-1171. (Pubitemid 47088777)
2. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182: 4499-4506.
3. Bhattacharya P, Gopisetty A, Ganesh BB, et al. GM-CSFinduced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol. 2011;89:235-249.
4. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59: 5160-5168. (Pubitemid 29503977)
5. Meidenbauer N, Harris DT, Spitler LE, et al. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 2000;43: 88-100. (Pubitemid 30220611)
6. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
7. Urba WJ, Nemunaitis J, Marshall F, et al. Treatment of biochemical recurrence of prostate cancer with granulocytemacrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol. 2008;180:2011-2017.
8. Higano CS, Shellhammer PF, Small EJ, et al. Integrated data from 2 randomized double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
9. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:1738-1744. (Pubitemid 29334454)
10. Rini BI, Weinberg V, Bok R, et al. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocytemacrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99-105.
11. Dreicer R, See WA, Klein EA. Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs. 2001;19:261-265. (Pubitemid 32781207)
12. Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18:226-232. (Pubitemid 46323086)
13. Davidson-Moncada J, Papavasiliou FN, Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci. 2010;1183:183-194.
14. Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306.
15. O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. Blood. 2011;118:2960-2969.
16. Kirman I, Belizon A, Balik E, et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. Eur J Surg Oncol. 2007;33: 1169-1176. (Pubitemid 350091353)
17. Garcia JA, Klein EA, Magi-Galluzzi C, et al. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res. 2008;14:3052-3059.
18. Hasskamp JH, Elias EG, Zapas JL. In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma. J Clin Immunol. 2006;26:331-338. (Pubitemid 44051380)
19. Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood. 2002;87-94.
20. Daud AI, Mirza N, Lenox B, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008;26: 3235-3241.
21. Roth MD, Gitlitz BJ, Kiertscher SM, et al. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000;934-941.
22. Esashi E, Wang YH, Perng O, et al. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity. 2008;28: 509-520.
23. Mahnke K, Qian Y, Knop J, et al. Induction of CD4 +CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood. 2003;101:4862-4869. (Pubitemid 36857748)
24. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumorinduced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med. 2002;196:541-549.
25. Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036-7044.
26. Faries MB, Hsueh EC, Ye X, et al. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009;15:7029-7035.
27. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337-6343. (Pubitemid 39129439)
28. Vuk-Pavlović S, Bulur PA, Lin Y, et al. Immunosuppressive CD14+HLA-DRlow/monocytes in prostate cancer. Prostate. 2010;70:443-455.
29. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocytemacrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546-2553. (Pubitemid 47041228)
30. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16:126-133. (Pubitemid 43247967)
31. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumorbearing host. Cancer Res. 2006;66:1123-1131. (Pubitemid 43165981)
32. Bowne WB, Wolchok JD, Hawkins WG, et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell Mol Ther. 1999;5:217-225. (Pubitemid 30330563)
33. Daro E, Pulendran B, Brasel K, et al. Polyethylene glycolmodified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol. 2000;165:49-58. (Pubitemid 30429489)
34. Golumbek PT, Azhari R, Jaffee EM, et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993;53:5841-5844. (Pubitemid 24006144)
35. Abe J, Wakimoto H, Yoshida Y, et al. Anti-tumor effect induced by GM-CSF gene modified tumor vaccination: comparison of adenovirus-and retrovirus mediated genetic transduction. J Cancer Res Clin Oncol. 1995;121:587-592.
36. Hess G, Kreiter F, Kosters W, et al. The effect of granulocytemacrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat. 1996;3:149-153. (Pubitemid 126734182)
37. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
38. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res. 2000;7:1181-1191. (Pubitemid 32708668)
39. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451:1125-1129. (Pubitemid 351317447)
40. Liu Q, Zhang M, Jiang X, et al. miR-223 suppresses differentiation of tumor-induced CD11b(+)Gr1(+)myeloid derived suppressor cells from bone marrow cells. Int J Cancer. 2011;129:2662-2673.
41. Guo S, Lu J, Schlanger R, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA. 2010;107:14229-14234.
42. Monk CE, Hutvagner G, Arthur JS. Regulation of miRNA transcription in macrophages in response to Candida albicans. PLoS One. 2010;5:e13669.
43. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208:1189-1201.
44. Williams AE, Perry MM, Moschos SA, et al. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 2008;36:1211-1215.
45. Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142:914-929.
46. Lin SL, Chiang A, Chang D, et al. Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008;14:417-424. (Pubitemid 351397806)
47. O'Connell RM, Kahn D, Gibson WS, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33:607-619.
48. Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity. 2009;31:220-231.
49. O'Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007;104:1604-1609. (Pubitemid 46214637)
50. Lu C, Huang X, Zhang X, et al. miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117:4293-4303.